• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors

    7/21/21 7:30:00 AM ET
    $AXNX
    $BLFS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXNX alert in real time by email

    BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company's chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors.

    Mr. Cohen has over 40 years' experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX).

    In addition, two other accredited public company directors and experienced life science executives have been added to the Company's board of directors.

    Andrew G. Hinson currently serves as a member of the board of directors at BioLife Solutions, Inc. (NASDAQ:BLFS). Mr. Hinson has over 30 years' experience in pharmaceutical, biotechnology and medical device development that includes specific expertise in congestive heart failure, clinical research and development, regulatory affairs, and business development. Hinson holds a B.S. in Biological Sciences from the University of Cincinnati.

    Rinda K. Sama currently serves as the chief operating officer of Axonics, Inc. Mr. Sama has over 20 years' experience in medical devices and is an expert in manufacturing and operations, as well as worldwide regulatory affairs. Sama holds a M.S. in Biomedical Engineering from the University of Southern California and an MBA from the University of California, Irvine.

    "This is an important time in the Company's history. BioVentrix has an accomplished and experienced CEO in Jim Dillon who now has a number of industry experts to provide support and guidance as the Company seeks to complete its PMA study, gain FDA approval and execute a successful IPO," said Raymond W. Cohen, chairman of BioVentrix.

    The additions of Mr. Sama and Mr. Hinson brings the total of independent medical device industry experts on the BioVentrix board to six, including CEO Jim Dillon and current board members, Steve Healy and George Fazio.

    Jim Dillon, CEO of BioVentrix, commented, "The Revivent TC™ system, which has achieved Breakthrough Designation by the U.S. FDA, is designed to treat congestive heart failure (CHF) patients with an enlarged left ventricle for which, until now, there has been no treatment. Clinical results continue to be impressive and reimbursement is already in place. We believe the combination of these factors will allow for a highly successful commercialization and rapid adoption in the United States."

    About Cardiomyopathy

    Cardiomyopathy represents a collection of diverse conditions of the heart muscle. These diseases have many causes, and symptoms that affect people of all ages and races. When cardiomyopathy occurs, the normal muscle in the heart can thicken, stiffen, thin out, or fill with substances the body produces that do not belong in the heart. As a result, the heart muscle's ability to pump blood is reduced, which can lead to an irregular heart rhythm, the backup of blood into the lungs or rest of the body, and death. Cardiomyopathy can be acquired—developed because of another disease, condition, or factor—or inherited. The cause is not always known.

    About BioVentrix

    BioVentrix, Inc., is a privately held medical device company headquartered in San Ramon, California. The Company's mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy. BioVentrix's Revivent TC™ system received the CE Mark and is currently pending FDA approval in the United States.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005165/en/

    Get the next $AXNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXNX
    $BLFS

    CompanyDatePrice TargetRatingAnalyst
    BioLife Solutions Inc.
    $BLFS
    9/30/2024$29.00Buy
    H.C. Wainwright
    BioLife Solutions Inc.
    $BLFS
    4/4/2024$22.00Buy
    Jefferies
    Axonics Inc.
    $AXNX
    1/9/2024Outperform → Peer Perform
    Wolfe Research
    Axonics Inc.
    $AXNX
    7/19/2023$69.00Outperform
    Robert W. Baird
    Axonics Inc.
    $AXNX
    7/13/2023$70.00Overweight
    KeyBanc Capital Markets
    BioLife Solutions Inc.
    $BLFS
    7/11/2023$29.00Buy
    Craig Hallum
    Axonics Inc.
    $AXNX
    5/23/2023$75.00Buy
    CL King
    Axonics Inc.
    $AXNX
    4/14/2023$75.00Buy
    Mizuho
    More analyst ratings

    $AXNX
    $BLFS
    Financials

    Live finance-specific insights

    See more
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

      Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position a

      4/7/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXNX
    $BLFS
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioLife Solutions Inc.

      10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:20:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:10:31 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.

      10-K/A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      4/8/25 4:34:04 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXNX
    $BLFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Large owner Casdin Partners Master Fund, L.P.

      4/A - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/29/25 9:57:30 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Wichterman Troy sold $18,743 worth of shares (932 units at $20.11), decreasing direct ownership by 0.49% to 188,310 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:43 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP & Chief Scientific Officer Mathew Aby J. sold $11,443 worth of shares (569 units at $20.11), decreasing direct ownership by 0.18% to 309,007 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:33 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXNX
    $BLFS
    Leadership Updates

    Live Leadership Updates

    See more

    $AXNX
    $BLFS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AXNX
    $BLFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AXNX
    $BLFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AXNX
    $BLFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

      BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

      3/18/25 8:30:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

      Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

      7/25/24 8:00:00 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      10/23/23 5:42:32 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Updates Earnings Call Information

      BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our exper

      5/8/25 4:32:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • H.C. Wainwright initiated coverage on BioLife Solutions with a new price target

      H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

      9/30/24 7:39:39 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on BioLife Solutions with a new price target

      Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00

      4/4/24 7:31:02 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axonics Modulation downgraded by Wolfe Research

      Wolfe Research downgraded Axonics Modulation from Outperform to Peer Perform

      1/9/24 6:49:41 AM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      2/13/24 5:00:45 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/13/24 4:59:03 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Axonics Inc. (Amendment)

      SC 13G/A - Axonics, Inc. (0001603756) (Subject)

      2/12/24 12:03:27 PM ET
      $AXNX
      Medical/Dental Instruments
      Health Care